Key Points
epilepsy
EPILEPSY

Safety and tolerability of IV lacosamide infusions were evaluated in 103 pediatric patients (≥1 month to <17 years of age) with epilepsy.Seventy‐nine (76.7%) patients had one IV lacosamide infusion, 20 (19.4%) had two, one (1.0%) had three, and three (2.9%) had 10 infusions.The only TEAEs reported in ≥2 patients were increased blood triglycerides. No serious, severe, or drug‐related TEAEs were reported.No consistent or clinically relevant changes were observed for hematology, clinical chemistry parameters, vital signs, or 12‐lead ECGs.IV lacosamide was generally well tolerated, and no new safety concerns were identified.